National Institute for Cellular Biotechnology Dublin City University, Glasnevin, Dublin 9, Ireland.
Curr Mol Med. 2011 Jun;11(4):286-303. doi: 10.2174/156652411795677954.
The discovery of new biomarkers is a rapidly advancing area in cancer biology. The challenge of biomarker development for broad clinical use requires the translation of lab-based knowledge into clinical practice. The Long Interspersed Nuclear Elements-1 (LINE-1s or L1 elements) are active members of an autonomous family of non-LTR retrotransposons and occupy nearly 17% of the human genome. There is strong experimental evidence that the global hypomethylation of genomic DNA in cancer cells results in the activation of L1s and their expression is detectable at genome, transcriptome and proteome levels in human cancer cells. Thus, human L1s constitute a potential marker for cancer cells. In this review we have attempted to scrutinize L1 expression profiles in clinical cancer studies by undertaking a comprehensive systematic analysis of papers published in the field so far with a view to providing a more complete picture of the detection methods used, improvements achieved and potential future directions. Ultimately, we will try to evaluate the potential of L1s as a molecular marker in cancer detection.
新生物标志物的发现是癌症生物学中一个迅速发展的领域。将基于实验室的知识转化为临床实践,这是广泛应用于临床的生物标志物开发所面临的挑战。长散布核元件-1(LINE-1s 或 L1 元件)是自主的非 LTR 反转录转座子家族的活跃成员,占据人类基因组的近 17%。有强有力的实验证据表明,癌细胞中基因组 DNA 的整体低甲基化导致 L1 的激活,并且在人类癌细胞的基因组、转录组和蛋白质组水平上可以检测到它们的表达。因此,人类 L1 构成了癌细胞的潜在标志物。在这篇综述中,我们试图通过对迄今为止发表的该领域的论文进行全面系统的分析,来仔细审查临床癌症研究中的 L1 表达谱,以期更全面地了解所使用的检测方法、取得的进展和潜在的未来方向。最终,我们将尝试评估 L1 作为癌症检测中分子标志物的潜力。